Polaryx Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-21.3%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.22next fiscal year
Monitoring Framework
Key Performance Indicators
Initiation of Phase 2 SOTERIA Basket Trial QuarterlyTarget: Launch trial in 2H 2026
Cash Runway Extension QuarterlyTarget: Extend operations through Q2 2027
Watch Items
- SOTERIA Phase 2 Basket Trial LaunchTrigger: Initiation of patient dosing in 2H 2026Action: Monitor clinical trial registry updates and company press releases for first patient dosed.
- Going Concern Status and Cash Burn RateTrigger: Cash balance falling below $3 million without additional non-dilutive or equity fundingAction: Review quarterly 10-Q filings to assess if the going concern warning is lifted or if further dilution is imminent.
Research as of 24 Jul 2026